Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) & NEXLIZET (bempedoic acid & ezetimibe) Prior to April 19, 2040

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) & NEXLIZET (bempedoic acid & ezetimibe) Prior to April 19, 2040

FinvizFinviz2026/02/17 13:03
By:Finviz

ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Alkem has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.

The pending patent litigation against the remaining defendants (Aurobindo Pharma Limited (along with an affiliate); MSN Pharmaceuticals Inc. (along with an affiliate); Renata Limited; and Sandoz Inc.) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a generic version of NEXLETOL and/or NEXLIZET, as applicable, to be marketed in the U.S. prior to April 19, 2040.

Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.

With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The script at the end of 2018: The Federal Reserve continued to raise interest rates, US stocks plunged 20% from the September highs, forcing the Federal Reserve to "pivot" in January.

Goldman Sachs' head of trading believes the current US stock market is repeating the scenario of late 2018, with monetary tightening and equity market pressure. The Goldman Sachs Financial Conditions Index has tightened by about 8 points in two weeks, reaching the highest level in a year. The selloff has broadened from tech stocks to defensive sectors. Gold and equities are declining simultaneously, possibly indicating investors are selling assets to raise cash, making gold a key indicator for observing liquidity stress.

华尔街见闻•2026/11/21 05:31
The script at the end of 2018: The Federal Reserve continued to raise interest rates, US stocks plunged 20% from the September highs, forcing the Federal Reserve to "pivot" in January.

Goldman Sachs Trader “Revisits the 2018 Playbook”: Still Clearly Remembers “On December 24th, Clients Asked Why the Market Dropped So Much—And I Had No Idea”

Brian Garrett pointed out that the current adjustment in the US stock market is similar to the sharp decline in Q4 2018: the S&P 500 has already experienced 42% of the corresponding drop, and the VIX is approaching its peak just before Christmas. If history repeats itself, the bottom of this cycle may appear in January next year. However, the credit market and Federal Reserve policy have yet to provide clear signals of a bottom.

华尔街见闻•2026/11/21 03:51

Anthropic (ANT.US) nearly “broke issue price,” but Claude knocks on the doors of “the highest peak in mathematics”! 17 million lines of Lean code used to write a candidate proof for the Riemann Hypothesis

On November 20th, Eastern Time, on its second day of trading, Anthropic's intraday price dropped to a low of $83.05, just 5 cents above the offering price of $83, and finally closed at $88.91, a decline of 8.50%. On the same day, the company's mathematician Levant Alperg announced on his personal website that he and Claude had found a candidate proof for the Riemann hypothesis, which has puzzled the mathematics community for 167 years, and released about 17 million lines of Lean formalized code.

智通财经•2026/11/21 03:21
Anthropic (ANT.US) nearly “broke issue price,” but Claude knocks on the doors of “the highest peak in mathematics”! 17 million lines of Lean code used to write a candidate proof for the Riemann Hypothesis

As US stocks plummet, the parent company of GTA 6 rises against the market! First-day sales hit a record $3.79 billion; Wall Street shifts focus to next-generation GTA Online.

According to Rentrak data, the global box office of "Grand Theft Auto VI" has also surpassed that of "Avengers: Endgame," the highest-grossing film of all time, which has a global box office of approximately $2.94 billion.

智通财经•2026/11/21 02:41
As US stocks plummet, the parent company of GTA 6 rises against the market! First-day sales hit a record $3.79 billion; Wall Street shifts focus to next-generation GTA Online.